Oncotelic Therapeutics (OTLC) Net Income Attributable to Noncontrolling Interests (2020 - 2026)
Oncotelic Therapeutics (OTLC) recorded Income from Non-Controlling Interests of -$47,136 in Q2 2026, compared with -$67,407 a year earlier.
Powered by 
Analysis
Oncotelic Therapeutics (OTLC) Net Income Attributable to Noncontrolling Interests (2020 - 2026) Analysis & Trends
On a TTM basis, Oncotelic Therapeutics' Income from Non-Controlling Interests came in at -$236,505 as of Jun 30, 2026; for FY2025, it came in at -$254,917.
- Across earlier years, Income from Non-Controlling Interests came in at -$255,527 in FY2024, -$302,972 in FY2023, -$418,378 in FY2022 and -$1.13 million in FY2021.
- The Q2 2026 figure is the highest quarterly Income from Non-Controlling Interests since Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCI Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,231.10 Bn | 1,204.71 Bn | 20.46 Bn | - |
| 2 | Johnson & Johnson | 669.11 Bn | 588.97 Bn | 17.30 Bn | - |
| 3 | AbbVie | 513.20 Bn | 481.21 Bn | 13.12 Bn | 2.00 Mn |
| 4 | Merck | 361.72 Bn | 324.66 Bn | 13.19 Bn | 2.00 Mn |
| 5 | Novartis Ag | 313.59 Bn | 286.83 Bn | - | - |
| 6 | Astrazeneca | 290.36 Bn | 264.25 Bn | 13.26 Bn | -1.00 Mn |
| 7 | Amgen | 246.51 Bn | 198.16 Bn | 7.58 Bn | - |
| 8 | Gilead Sciences | 206.71 Bn | 181.82 Bn | 6.73 Bn | - |
| 9 | Pfizer | 165.30 Bn | 112.66 Bn | 12.56 Bn | 10.00 Mn |
| 10 | Oncotelic Therapeutics | 4.57 Mn | 2.62 Mn | - | -47,136.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -47,136.00 |
| Dec 31, 2025 | -54,958.00 |
| Sep 30, 2025 | -67,004.00 |
| Jun 30, 2025 | -67,407.00 |
| Mar 31, 2025 | -65,548.00 |
| Dec 31, 2024 | -53,527.00 |
| Sep 30, 2024 | -67,165.00 |
| Jun 30, 2024 | -68,336.00 |
| Mar 31, 2024 | -66,499.00 |
| Dec 31, 2023 | -55,089.00 |
| Sep 30, 2023 | -74,248.00 |
| Jun 30, 2023 | -93,010.00 |
| Mar 31, 2023 | -80,625.00 |
| Dec 31, 2022 | -54,913.00 |
| Sep 30, 2022 | -81,501.00 |
| Jun 30, 2022 | -41,424.00 |
| Mar 31, 2022 | -240,540.00 |
| Dec 31, 2021 | -176,953.00 |
| Sep 30, 2021 | -293,001.00 |
| Jun 30, 2021 | -336,737.00 |
API Access
Oncotelic Therapeutics Net Income Attributable to Noncontrolling Interests API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=OTLC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-non-controlling-interests", "ticker": "OTLC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=OTLC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();